During the last session, Larimar Therapeutics Inc (NASDAQ:LRMR)’s traded shares were 1.05 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $7.14, reflecting an intraday gain of 4.23% or $0.29. The 52-week high for the LRMR share is $13.68, that puts it down -91.6 from that peak though still a striking 69.47% gain since the share price plummeted to a 52-week low of $2.18. The company’s market capitalization is $455.60M, and the average intraday trading volume over the past 10 days was 0.64 million shares, and the average trade volume was 523.52K shares over the past three months.
Larimar Therapeutics Inc (LRMR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. LRMR has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Larimar Therapeutics Inc (NASDAQ:LRMR) trade information
Larimar Therapeutics Inc (LRMR) registered a 4.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.23% in intraday trading to $7.14, hitting a weekly high. The stock’s 5-day price performance is -1.38%, and it has moved by -8.58% in 30 days. Based on these gigs, the overall price performance for the year is 71.63%. The short interest in Larimar Therapeutics Inc (NASDAQ:LRMR) is 3.47 million shares and it means that shorts have 11.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.5, which implies an increase of 50.76% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $25 respectively. As a result, LRMR is trading at a discount of -250.14% off the target high and 43.98% off the low.
Larimar Therapeutics Inc (LRMR) estimates and forecasts
Statistics show that Larimar Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Larimar Therapeutics Inc (LRMR) shares have gone down -16.30% during the last six months, with a year-to-date growth rate less than the industry average at -66.67% against 20.70. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -81.00% this quarter and then drop -36.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 48.33%. While earnings are projected to return -71.44% in 2024.
LRMR Dividends
Larimar Therapeutics Inc is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Larimar Therapeutics Inc (NASDAQ:LRMR)’s Major holders
Larimar Therapeutics Inc insiders own 1.45% of total outstanding shares while institutional holders control 108.07%, with the float percentage being 109.66%. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is the largest shareholder of the company, while 143.0 institutions own stock in it. As of 2024-06-30, the company held over 21.23 million shares (or 39.6461% of all shares), a total value of $153.93 million in shares.
The next largest institutional holding, with 6.05 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 11.2884% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $43.83 million.
